The paper by Kim et al. [9], mentioned by the author to support the claim that SDF-1α-mediated neovascularization in diabetic neuropathy in detrimental to the course of this complication, actually provides evidence that stem cell mobilization with plerixafor is a therapeutic option against diabetic neuropathy, a concept that is being tested in ongoing trials. Here, CXCL12 is linked to diabetic neuropathy.